Facebook
Twitter
LinkedIn
ForwardInaugural Miami Cancer Institute Summit of the Americas on Immunotherapies for Hematologic Malignancies
Given the increasing frequency of hematologic malignancies, complexities of treatments with novel agents and particularly with immunotherapeutic approaches, there is a need to provide an opportunity for oncologists, hematologists, oncology nurses and pharmacists to engage in a thoughtful discussions with experts in these fields. In addition, there is emerging data about the biology of these malignancies impacting optimal management of patients with these disorders. Clinical decision making and management therefore has become more complex.
This one-and-a-half-day symposium has been designed to provide an overview and opportunity to learn about the most recent advances in the treatment of leukemia, lymphoma, multiple myeloma and stem cell transplantation by novel immunotherapies and treatment combinations. Updates on evolving immunologically and molecular based system therapies will be profiled and discussed.
Complete details at MiamiCancerInstitute.com/HematologicMalignancies
Registration Fees
| Physicians | Baptist Health Employees | Other Healthcare Professionals | Fellows and Students | International Physicians | International Other | |
| Registration Fees | $325 | $55 | $165 | $95 | $228 | $116 |
Target Audience
This educational program is directed toward hematologists, oncologists, pathologists, radiation oncologists, palliative care staff, medical oncology, hematology nurses, pharmacists and other allied health care professionals interested in the treatment of patients with hematologic malignancies.
Learning Objectives
- Summarize the evolving therapeutic strategies in the treatment of hematologic malignancies.
- Provide an update of new molecular and immunological treatments being developed for these diseases.
- Discuss the rationale for new targeted diagnostic and therapeutic strategies for lymphoma, myeloma and leukemia.
- Review the role and timing of hematopoietic cell transplantation and potential combinations of immunotherapeutic treatment options.
Directors
Guenther Koehne, M.D., Ph.D.
Co-Director
Robert Sackstein, M.D., Ph.D.
Faculty
Adam D. Cohen, M.D.
Assistant Professor, Medicine
Abramson Cancer Center
University of Pennsylvania
Philadelphia, Pennsylvania
Nitin Jain, M.D.
Associate Professor of Medicine
Department of Leukemia
MD Anderson Cancer Center
Houston, Texas
Guenther Koehne M.D., Ph.D.
Deputy Director of Miami Cancer Institute
Chief of Blood & Marrow Transplant and Hematologic Oncology
Miami Cancer Institute
Miami, Florida
Ola Landgren, M.D., Ph.D.
Professor of Medicine
Chief, Myeloma Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York
Richard O’Reilly, M.D.
Claire L. Tow Chair in Pediatric Oncology Research
Attending Physician
Memorial Sloan Kettering
New York, New York
Susan E. Prockop, M.D.
Pediatric Oncology; Allogeneic and Autologous Bone Marrow and
Peripheral Blood Stem Cell Transplantation
Congenital and Acquired Diseases of Hematopoiesis and Immunity
Memorial Sloan Kettering
New York, New York
Katy Rezvani, M.D.
Professor of Medicine
Chief of Section of Cellular Therapy
MD Anderson
Houston, Texas
Paul G. Richardson, M.D.
Medical Oncologist
Dana-Farber Cancer Institute
Boston, Massachusetts
Robert Sackstein, M.D., PhD.
Interim Chair, Department of Translational Medicine
Dean and Senior Vice President for Health Affairs, and Professor
Florida International University
Miami, Florida
Michel W. Saldelain, M.D., Ph.D.
Director Center for Cell Engineering
Memorial Sloan Kettering
New York, New York
Elizabeth J. Shpall, M.D.
Cancer Center Support Grant Programs
Stem Cell Transplantation
Brain Cancer
MD Anderson Cancer Center
Houston, Texas
Robert Soiffer, M.D.
Professor of Medicine
Harvard Medical School
Chief - Division of Hematologic Malignancies
Brigham and Women’s Hospital
Boston, Massachusetts
Eytan M. Stein, M.D.
Hematologic Oncologist
Memorial Sloan Kettering
New York, New York
Wendy Stock, M.D.
Anjuli Seth Nayak Professor of Medicine,
Section of Hematology/Oncology
University of Chicago
Chicago, Illinois
Marty Tallman, M.D.
Chief, Leukemia Service
Memorial Sloan Kettering
Professor of Medicine
Weil Cornell Medical College
New York, New York
Kate Markey, MBBS, Ph.D.
Hematologist
Memorial Sloan Kettering
Anas Younes, M.D.
Chief Lymphoma Service
Memorial Sloan Kettering
New York, New York
Non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant relationships with commercial interest companies.
Baptist Health South Florida is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Baptist Health has been re-surveyed by the ACCME and awarded Commendation for 6 years as a provider of CME for physicians.
Baptist Health South Florida designates this live activity for a maximum of 10 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Price
Registration Fees
| Physicians | Baptist Health Employees | Other Healthcare Professionals | Fellows and Students |
| $325 | $55 | $165 | $95 |
Cancellation Policy
Changes may occur that are beyond our control. In the unforeseen event the symposium is canceled, Baptist Health will refund attendees the entire amount of their registration fees. If you are traveling from outside of the area, we strongly suggest purchasing travel insurance.
Cancellations must be received by January 9, 2020 to receive a refund of the registration fee, less a $25 administrative fee. Registration fees are not refundable after January 9, 2020.
Required Hardware/Software
If you are not able to register, please look in the upper right to see if there is something in your shopping cart.
Technical Support: If you are experiencing technical difficulties or have received an error message, please send an email to CME@BaptistHealth.net and include a print screen of the error message, your browser name and version, username and URL where the error occurred. You can expect a response within 48 hours.